DrugPatentWatch Database Preview

VIIBRYD Drug Profile

Email this page to a colleague

« Back to Dashboard

When do Viibryd patents expire, and when can generic versions of Viibryd launch?

Viibryd is a drug marketed by Allergan and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has sixty patent family members in twenty-nine countries.

The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.

US ANDA Litigation and Generic Entry Outlook for Viibryd

A generic version of VIIBRYD was approved as vilazodone hydrochloride by ALEMBIC PHARMS LTD on January 10^th, 2020.

Summary for VIIBRYD

International Patents:	60
US Patents:	4
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	68
Clinical Trials:	16
Patent Applications:	35
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for VIIBRYD
Drug Sales Revenues:	Drug sales revenues for VIIBRYD
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIIBRYD
DailyMed Link:	VIIBRYD at DailyMed

See drug prices for VIIBRYD

See drug sales revenues for VIIBRYD

Recent Clinical Trials for VIIBRYD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Forest Laboratories	Phase 1
New York State Psychiatric Institute	Phase 4
Forest Laboratories	Phase 3

See all VIIBRYD clinical trials

Recent Litigation for VIIBRYD

Identify potential future generic entrants

District Court Litigation

Case Name	Date
Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc.	2015-11-23
Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc.	2015-03-30
Forest Laboratories LLC v. Accord Healthcare Inc.	2015-03-27

See all VIIBRYD litigation

PTAB Litigation

Petitioner	Date
	2018-01-05

See all VIIBRYD litigation

Synonyms for VIIBRYD

1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride

1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)piperazine hydrochloride

1-[4-(5-cyanoindol-3-yl)butyl]4-(2-carbamoyl-benzofuran-5-yl)-piperazine hydrochloride

163521-08-2

2-Benzofurancarboxamide, 5-(4-(4-(5-cyano-1H-indol-3-yl)butyl)-1-piperazinyl)-, hydrochloride (1:1)

2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-, hydrochloride

2-Benzofurancarboxamide, 5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-, hydrochloride (1:1)

2794AH

4-(2-carbamoyl-1-benzofuran-5-yl)-1-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-ium chloride

5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide hydrochloride

5-(4-(4-(5-Cyano-1H-indol-3-yl)butyl)piperazin-1-yl)benzofuran-2-carboxamide monohydrochloride

5-(4-[4-(5-cyano-3-indolyl)-butyl]-1-piperazinyl)-benzofuran-2carboxamide hydrochloride

5-[4-[4-(5-Cyano-1H-indol-3-yl)butyl]-1-piperazinyl]-2-benzofurancarboxamide hydrochloride

5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]-1-benzofuran-2-carboxamide;hydrochloride

5-[4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride

5-[4-[4-(5-Cyanoindol-3-yl)butyl]piperazin-1-yl]benzofuran-2-carboxamide hydrochloride

5-{4-[4-(5-cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide hydrochloride

5-{4-[4-(5-Cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboximidic acid--hydrogen chloride (1/1)

521V128

A3919

AB0000947

AC-25885

AK161007

AKOS024464039

API0009252

AS-74699

AX8294006

BCP11496

C26H27N5O2.ClH

CCG-213313

CHEBI:70705

CHEMBL1615374

CS-0549

D09699

DTXSID80936833

EBD2199528

EMD 68 843

EMD 68843

EMD 68843;SB659746A

EMD-68843

HY-14261

J-525160

KS-00000SKE

LS-34922

Q27139037

RPZBRGFNBNQSOP-UHFFFAOYSA-N

s4259

SB 659746A

SB-659746-A

SB-659746A

SB659746-A

SB659746A

SCHEMBL867358

ST24050347

SW219887-1

U8HTX2GK8J

UNII-U8HTX2GK8J

Viibryd (TN)

Vilazodone (Hydrochloride)

Vilazodone HCl

Vilazodone hydrochloride

Vilazodone hydrochloride (USAN)

Vilazodone hydrochloride [USAN]

Vilazodone hydrochloride solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material

Vilazodone hydrochloride, >=98% (HPLC)

vilazodone monohydrochloride

vilazodone-hcl

Vilazodonei

Paragraph IV (Patent) Challenges for VIIBRYD

Tradename	Dosage	Ingredient	NDA	Submissiondate
VIIBRYD	TABLET;ORAL	vilazodone hydrochloride	022567	2015-01-21

US Patents and Regulatory Information for VIIBRYD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-001	Jan 21, 2011	AB	RX	Yes	Yes					Y
Allergan	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-003	Jan 21, 2011	AB	RX	Yes	No
Allergan	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011	AB	RX	Yes	No					Y
Allergan	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-001	Jan 21, 2011	AB	RX	Yes	Yes					Y
Allergan	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011	AB	RX	Yes	No
Allergan	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011	AB	RX	Yes	No					Y
Allergan	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-003	Jan 21, 2011	AB	RX	Yes	No					Y

Expired US Patents for VIIBRYD

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Allergan	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-001	Jan 21, 2011
Allergan	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011
Allergan	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-003	Jan 21, 2011

International Patents for VIIBRYD

Country	Patent Number	Estimated Expiration
Spain	2105454
Russian Federation	2004100824
Czech Republic	9402370
Ecuador	SP044943
Australia	7424494
Canada	2683040
Norway	306948